943138-96-3

Upstream product

• 1023699-50-4 [3-(2-methyl-piperidin-1-yl)-propyl]-(2-nitro-phenyl)-amine 

Downstream Products

• 1023699-11-7 2-benzyl-1-[3-(2-methyl-piperidin-1-yl)-propyl]-1H-benzimidazole 
• 1023699-12-8 2-(2-chloro-phenoxymethyl)-1-[3-(2-methyl-piperidin-1-yl)-propyl]-1H-benzimidazole 
• 1023699-22-0 2-(2-methoxyphenoxymethyl)-1-[3-(2-methyl-piperidin-1-yl)-propyl]-1H-benzimidazole 
• 1023699-14-0 2-(3-chloro-phenoxymethyl)-1-[3-(2-methyl-piperidin-1-yl)-propyl]-1H-benzimidazole 
• 1023699-08-2 2-(2-methoxy-benzyl)-1-[3-(2-methyl-piperidin-1-yl)-propyl]-1H-benzimidazole 
• 1023699-20-8 1-[3-(2-methyl-piperidin-1-yl)-propyl]-2-p-tolyloxymethyl-1H-benzimidazole 
• 1023699-16-2 2-(4-fluoro-phenoxymethyl)-1-[3-(2-methyl-piperidin-1-yl)-propyl]-1H-benzimidazole 
• 1023699-06-0 C₂₅H₃₄N₄ 
• 1023699-07-1 2-(2-fluoro-benzyl)-1-[3-(2-methyl-piperidin-1-yl)-propyl]-1H-benzimidazole 
• 1023699-18-4 1-[3-(2-methyl-piperidin-1-yl)-propyl]-2-phenoxymethyl-1H-benzimidazole 
• 1023699-09-3 2-(4-bromo-benzyl)-1-[3-(2-methyl-piperidin-1-yl)-propyl]-1H-benzimidazole 

Relevant academic research and scientific papers

Parallel synthesis of a series of potentially brain penetrant aminoalkyl benzoimidazoles

Alpha7 agonists were identified via GOLD (CCDC) docking in the putative agonist binding site of an alpha7 homology model and a series of aminoalkyl benzoimidazoles was synthesised to obtain potentially brain penetrant drugs. The array was prepared startin